Arcascope is a technology company.
Arcascope has raised $3.0M across 1 funding round.
Arcascope has raised $3.0M in total across 1 funding round.
Arcascope has raised $3.0M in total across 1 funding round.
Arcascope's investors include Supermoon Capital.
Arcascope is a healthcare technology company specializing in circadian rhythms and chronomedicine, developing advanced digital tools that leverage mobile phones and AI to provide personalized behavioral recommendations and precision dosing for improving sleep and health, particularly in shift workers and patients. Their flagship technologies include chronoRCT™, an AI platform that identifies drugs that failed due to mistimed dosing, and Arcasync™, a precision dosing engine that personalizes treatment timing using biospecimen and wearable data. Arcascope serves healthcare providers, pharmaceutical companies, and shift workers by addressing the critical problem of circadian misalignment, which affects drug efficacy and overall health. The company has demonstrated growth momentum through NIH funding, a $2.85 million seed round, and partnerships with research institutions, positioning itself at the forefront of circadian health innovation[1][2][3][4].
Founded in 2020 and headquartered in Chantilly, Virginia, Arcascope was established by a team of experts including three PhDs with deep backgrounds in circadian science. The idea emerged from the recognition that many drugs fail clinical trials due to incorrect dosing times relative to patients' biological clocks, and that wearable technology could noninvasively predict circadian timing to optimize treatment. Early traction came from NIH Small Business Innovation Research (SBIR) awards and collaborations with institutions like Henry Ford Health System, enabling the development of mathematical models and apps that provide personalized circadian recommendations for shift workers and cancer patients. This foundation has allowed Arcascope to evolve from a research-driven startup to a commercial innovator in chronomedicine[2][3][4].
Arcascope rides the growing trend of precision medicine and digital health, specifically targeting the emerging field of chronomedicine—the science of aligning medical treatments with biological timing. The timing is critical as wearable technology adoption and AI capabilities have matured, allowing scalable, personalized circadian analytics. Market forces such as increasing awareness of sleep health, the burden of shift work on public health, and pharmaceutical interest in improving drug trial success rates favor Arcascope’s solutions. By integrating circadian science with AI and digital tools, Arcascope influences the broader ecosystem by enabling new therapeutic approaches, improving drug development, and enhancing patient quality of life through personalized timing interventions[1][3][4].
Looking ahead, Arcascope is poised to expand its commercial rollout beyond shift workers into broader clinical applications, including cancer survivorship and drug repurposing. Trends in AI-driven personalized medicine and wearable health monitoring will shape its journey, potentially making circadian-informed treatment a standard in healthcare. As the company scales, its influence could grow from a niche chronomedicine innovator to a key player in precision dosing and digital therapeutics, transforming how timing is integrated into medical practice. This evolution ties back to Arcascope’s core mission: unlocking the power of biological timing to improve health outcomes through technology and science[2][3][4].
Arcascope has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $3.0M Seed | Supermoon Capital |